Kamada Ltd. (NASDAQ:KMDA) Receives Average Recommendation of “Strong Buy” from Brokerages
Shares of Kamada Ltd. (NASDAQ:KMDA) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus target price of $8.50 for the company and are predicting that the company will post ($0.04) EPS for the current quarter, according to Zacks. Zacks has also assigned Kamada an industry rank of 107 out of 265 based on the ratings given to related companies.
KMDA has been the topic of a number of research analyst reports. Zacks Investment Research raised Kamada from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Thursday, August 4th. TheStreet raised Kamada from a “sell” rating to a “hold” rating in a research note on Monday, September 26th. Jefferies Group reaffirmed a “buy” rating and issued a $7.00 price target on shares of Kamada in a research note on Wednesday, August 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Kamada in a research note on Saturday, September 3rd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/kamada-ltd-nasdaqkmda-receives-average-recommendation-of-strong-buy-from-brokerages.html
A number of institutional investors have recently made changes to their positions in KMDA. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Kamada during the second quarter worth approximately $1,701,000. Vanguard Group Inc. increased its position in shares of Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares during the last quarter. Hedge funds and other institutional investors own 5.31% of the company’s stock.
Shares of Kamada (NASDAQ:KMDA) traded up 0.76% during trading on Friday, reaching $5.29. The company’s stock had a trading volume of 15,875 shares. Kamada has a 1-year low of $3.26 and a 1-year high of $5.45. The company’s market capitalization is $192.65 million. The stock has a 50 day moving average of $4.82 and a 200-day moving average of $4.10.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The firm had revenue of $19.10 million for the quarter, compared to analyst estimates of $18.50 million. Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. On average, analysts expect that Kamada will post ($0.19) earnings per share for the current year.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.